Literature DB >> 29193151

Refractory myasthenia gravis exacerbation triggered By pembrolizumab.

Damien E Earl1,2, Aaron I Loochtan1,2, Richard S Bedlack1,2.   

Abstract

Entities:  

Keywords:  exacerbation; immune checkpoint inhibitor; immune-related adverse event; melanoma; myasthenia gravis; pembrolizumab

Mesh：

Substances：

Year:  2017        PMID： 29193151     DOI： 10.1002/mus.26021

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


× No keyword cloud information.
  7 in total

1.  Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma.

Authors:  Nozomi Hayakawa; Eiji Kikuchi; Shigeaki Suzuki; Mototsugu Oya
Journal:  Int Cancer Conf J       Date:  2020-03-21

2.  Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer.

Authors:  Makoto Hibino; Kazunari Maeda; Shigeto Horiuchi; Minoru Fukuda; Tetsuri Kondo
Journal:  Respirol Case Rep       Date:  2018-08-07

3.  Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

Authors:  Anne Zaremba; Eleftheria Chorti; Finja Jockenhöfer; Saskia Bolz; Selma Sirin; Martin Glas; Jürgen C Becker; Selma Ugurel; Alexander Roesch; Dirk Schadendorf; Elisabeth Livingstone; Tim Hagenacker; Lisa Zimmer
Journal:  J Immunother Cancer       Date:  2019-05-29       Impact factor: 13.751

Review 4.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03

5.  Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia.

Authors:  Koutaro Takamatsu; Shunya Nakane; Shigeaki Suzuki; Takayuki Kosaka; Satoshi Fukushima; Toshihiro Kimura; Azusa Miyashita; Akihiro Mukaino; Shiori Yamakawa; Keisuke Watanabe; Masatoshi Jinnin; Yoshihiro Komohara; Hironobu Ihn; Yukio Ando
Journal:  Ann Clin Transl Neurol       Date:  2018-09-23       Impact factor: 4.511

6.  Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis.

Authors:  Akiko Ishii; Minato Yokoyama; Hiroshi Tsuji; Yasuhisa Fujii; Akira Tamaoka
Journal:  eNeurologicalSci       Date:  2020-03-14

Review 7.  Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.

Authors:  Lin Zhou; Xin Wei
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.